It has been learned that Ontek Micro-Precision Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "Ontek Micro-Precision"), which focuses on ultra-microscopic and high-precision surgical robots, recently announced the completion of a B-round financing of several hundred million yuan. This round of financing was jointly participated in by industrial capital and well-known investment institutions, with Index Ventures' subsidiary, JinYi Internet, participating in the follow-on investment, and Chunmu Capital serving as the exclusive financial advisor. The funds will be mainly used to consolidate the technological advantages of core products, improve the ecosystem of microsurgical robot series products, accelerate the clinical registration process, and promote international market expansion.
Founded in 2022, Ontech Micro-Precision is the world's first innovative company focusing on small, precision surgical robot platforms. Its predecessor provided high-precision intelligent device R&D and manufacturing services to several internationally renowned medical device companies, accumulating over a decade of profound technical expertise in precision medical device manufacturing. Ontech Micro-Precision, in collaboration with R&D centers in the US and Japan, has independently developed the underlying components, servo systems, transmission mechanisms, and consumable components for surgical robots, breaking the bottleneck of reliance on imports for key technologies. Furthermore, the company has established deep collaborations with numerous universities and research institutions both domestically and internationally, jointly promoting the development of engineering components and systems, forming a complete innovation chain from underlying technology to clinical applications.
Ontech Micro-Precision focuses on the R&D of high-precision platform-type surgical robots, with a product line covering general-purpose microsurgical robots, ophthalmic surgical robots, and related innovative consumables for multidisciplinary robots. Its core technological breakthrough lies in achieving sub-micron level single-step motion accuracy and shaky operation throughout the procedure, equipped with a 7-DOF wrist joint design to adapt to the demanding operational needs of confined surgical spaces. These innovative products have taken the lead in global surgical robot technology and gained widespread recognition from clinicians in numerous top-tier hospitals. They have also established collaborations with leading medical institutions such as Shanghai Ninth People's Hospital, Ningbo Sixth People's Hospital, and Peking University School of Stomatology to jointly promote the application and optimization of surgical robots in clinical settings.
The human eye is extremely fragile, and the surgical space is extremely confined. Traditional ophthalmic surgery is limited by challenges such as physiological tremors of the surgeon's hand (human hands naturally exhibit approximately 100 micrometers of physiological shaking), the magnification limit of the field of vision, and fatigue errors, making it difficult to achieve more stable and precise breakthroughs.
Ontech Micro-Precision's independently developed ophthalmic surgical robot is a high-precision solution specifically designed to address these clinical pain points. Integrating high-precision control algorithms and flexible microstructures, Ontech Micro-Precision's ophthalmic surgical robot can achieve sub-micrometer-level single-step movements, effectively filtering out physiological tremors of the hand, helping surgeons overcome physiological limits, meeting the operational requirements of high-precision fundus surgery, shortening the surgeon's learning curve, exceeding the surgeon's skill ceiling, and improving surgical success rates.
It is reported that Ontech Micro-Precision's ophthalmic surgical robot has recently completed clinical registration and has officially entered the crucial stage of registration and market launch. Beyond ophthalmology, Ontech Microsurgery has also achieved rapid breakthroughs in microsurgical robots. According to public reports, the company's Kai microrobot covers multiple fields, including plastic and reconstructive surgery, maxillofacial surgery, hand surgery, and reconstructive surgery, demonstrating strong platform scalability and versatility.
This microrobot boasts multiple degrees of freedom and a compact size, allowing for rapid deployment in the operating room. Its front end can carry instruments such as the world's smallest clamps with seven degrees of freedom and a diameter of only 2 mm, enabling high-precision operations such as vascular and lymphatic anastomosis within 0.3 mm, maintaining sub-millimeter consistency even during long-duration operations. It features high-definition 3D stereoscopic vision, capable of identifying minute structures and tension changes. Its lightweight design facilitates positioning, allowing flexible access to restricted surgical fields such as deep head and neck areas and around small joints, while also supporting integrated deployment across multiple departments and educational applications.
The Ontech Microsurgical Robot has been validated in multiple clinical practices:
In June 2025, it assisted the Microsurgery Center of Shanghai Ninth People's Hospital in completing the world's first robot-assisted resection of a giant dermatofibrosarcoma protuberans;
In July 2025, it was successfully applied to Zhejiang Province's first domestically produced microsurgical robot-assisted ultra-thin perforator flap transplantation at Ningbo Sixth People's Hospital;
In July 2025, it successfully performed a fine anastomosis of the superficial temporal artery and posterior auricular vein at Shanghai Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, applied to the repair of complex scalp scars;
In September 2025, it supported Peking University School of Stomatology in completing China's first microsurgical robot-assisted maxillofacial vascularized free tissue flap reconstruction surgery.
These cases demonstrate that the robot exhibits good feasibility and stability in various clinical scenarios. It can not only serve as a specialized device but also has the potential to develop into a general-purpose surgical platform covering multiple disciplines and surgical procedures, promoting the popularization of complex surgical procedures. Currently, the device is still in the clinical validation stage, and the company plans to further expand its indications and continuously optimize system performance through cooperation with authoritative medical institutions. Over the past decade, China's surgical robot industry has evolved from its initial stage, represented by laparoscopy and orthopedics, to expansion into emerging areas such as interventional and transoral surgical procedures. As the market matures, refinement, platformization, and multidisciplinary expansion are becoming the focus of the new round of competition.
Agatech Micro-Precision has chosen ophthalmology and microsurgery, fields with higher barriers to entry but urgent clinical needs. This allows it to enter a differentiated market while also having the potential to amplify its platform technology advantages. Its independent R&D accumulation in core components, control algorithms, force feedback, and microsurgical operating systems lays a technological foundation for subsequent expansion into multiple fields.
Surgical robots have entered a stage of refined development. Future opportunities lie not only in large-scale applications but also in solving clinical "pain point surgeries." Gatech Micro-Precision's accelerated deployment in clinical application and surgical procedure expansion is expected to drive breakthroughs in the high-precision surgical robot industry.
Regarding this round of financing, the founder of Onte Micro-Precision stated: "Our successful Series B financing is primarily due to investors' affirmation of the perfect success rate and zero errors achieved in surgeries using our first two surgical robots. It also reflects their confidence in our ability to further expand our surgical procedures in this field and enter the commercial market. Furthermore, it provides a strong impetus for our next step into the neurosurgery field!"
Springwood Capital stated: "Onte Micro-Precision has steadfastly chosen the difficult but correct path, diligently cultivating the field of high-value surgical robots throughout its long technological journey. The team has not only achieved a high degree of technological independence and leadership, but also accelerated breakthroughs in clinical application and global expansion. Its products redefine surgical accessibility and precision, providing revolutionary solutions for doctors and patients worldwide. We believe that Onte Micro-Precision's journey from 'seeing the first glimmer of light' to 'creating a new dawn,' its long-termism and relentless pursuit of excellence, will undoubtedly lead to industry transformation." We look forward to their continued dedication and daily improvement, until they achieve excellence!
JinYi Interactive CEO Zheng Li stated: "JinYi Interactive firmly believes that surgical robots can bring enormous benefits to human healthcare and has been seeking partners. At the same time, I also see that realizing the practical application of high-precision surgical robots to benefit patients and doctors is a very challenging and demanding process. Seeing Onte Micro's long-term, high-level accumulated datasets, the team's efficient and low-cost modeling capabilities, the high recognition from the market and hospitals, and the team's resilience and breakthrough capabilities in histopathology, we were immediately impressed. We are firmly optimistic about the company's future value and expect the company to use the gold standard of pathology as an entry point to create the best surgical robot products for global users, bringing Onte Micro to every hospital worldwide and benefiting everyone globally."
